What Injections for Macular Degeneration Can Realistically Do: Slowing Loss, Not Undoing It

Ruth noticed it on a Tuesday, reading the paper. The vertical rule between the columns had developed a kink, as if the page had been folded and not quite flattened. She closed her right eye and the kink was still there. She closed her left eye and it vanished. Three weeks later she was sitting under a bright lamp in a retina clinic, hearing the words ‘injection into the eye’ and trying very hard to keep her face neutral.

Her first question was the one nearly everyone asks: will this bring my sight back? Her second, a beat later, was: and if not, what is it for? Both deserve honest answers, and honest answers about macular degeneration injections results are less dramatic than the promise and far better than the fear.

This explainer walks through what the injections do in the eye, what the trials measured, why scar tissue sets a ceiling on recovery, and how to read your own scans and visits with clear expectations. Every decision about starting, spacing or pausing treatment rests with your retina team; the aim here is to make their conversation with you easier to follow.

Why does wet macular degeneration need injections at all?

The macula is the pinhead-sized patch at the center of the retina that handles reading, recognizing faces and threading a needle. It is tiny, metabolically hungry and easily disturbed. In age-related macular degeneration (AMD), the tissue that nourishes it wears down over decades. Most people have the dry form, where waste deposits called drusen build up and cells slowly thin. A smaller group develop the wet form, and this is the version the injections are built for.

Wet AMD begins when abnormal blood vessels sprout from beneath the retina, a process called choroidal neovascularization. These vessels are badly made. They leak fluid and blood into and under the macula, and the light-sensing cells sitting in that puddle stop working properly. Straight lines bend, a gray or blank spot appears in the center, and the change can unfold over weeks rather than years. The National Eye Institute describes wet AMD as the less common but faster-moving form.

The vessels grow because of a chemical signal. Vascular endothelial growth factor, or VEGF, is a protein the body uses to build blood vessels where it believes they are needed. In the aging macula it is released in the wrong place. Anti-VEGF medicines are antibody-like molecules that bind that protein so it cannot deliver its message. Starve the leaky vessels of their growth signal and they tend to stop leaking, and often shrink.

Why a needle rather than a pill or a drop? The retina sits behind barriers that keep most substances in the bloodstream out, and drops on the surface do not reach the back of the eye in useful amounts. Placing the medicine directly into the vitreous, the clear gel that fills the eyeball, puts it where it is needed while keeping the rest of the body largely out of the picture. That is the whole logic of the treatment, and it also explains its central limitation: it acts on the leak, not on cells already gone.

What happens during anti-VEGF injections for wet AMD

Most people find the idea worse than the event. The injection itself takes a few seconds; the visit around it takes considerably longer, and it helps to know which part is which.

A typical appointment starts with a letter-chart check and a scan called optical coherence tomography (OCT), a painless light-based scan that draws a cross-section of the retinal layers and shows fluid pockets that no torch or mirror could reveal. The retina specialist compares today’s scan with your earlier ones. That comparison, more than how your vision feels on the day, usually drives the decision to inject.

Then the preparation: numbing drops, sometimes a small numbing gel or a tiny anesthetic injection under the surface, and an antiseptic wash, usually a brown iodine solution, over the eye and lids. Antisepsis is the single most important safety step, which is why the eye often stings and feels dry afterward; the iodine, not the needle, is the usual culprit. A small clip called a speculum holds the lids open so a blink cannot arrive at the wrong moment.

The needle enters through the white of the eye, the sclera, a few millimeters from the colored iris and never through the pupil. People generally describe pressure or a brief sting rather than pain. You may see a dark swirl or new floaters as the medicine enters the gel, and light may dim for a moment. Some services check eye pressure afterward, because the added volume can raise it briefly.

Then you go home, usually with advice about lubricating drops and a phone number for problems. Some services treat both eyes on the same day; others prefer separate visits. Either way, arrange a ride. The treated eye will be blurry, and bright light will bother it for a few hours.

What macular degeneration injections results look like on the eye chart

Eye clinics measure vision in letters. Five letters make one line on the standard chart, and a change of 15 letters, three full lines, is the threshold researchers treat as clearly meaningful to a person’s daily life. Keeping those units in mind makes the trial numbers readable.

The largest independent head-to-head trial of anti-VEGF treatment for wet AMD, the Comparison of AMD Treatments Trials (CATT), followed more than a thousand people. At one year, eyes given monthly injections had gained on average about eight letters, roughly a line and a half. Between one in four and one in three eyes gained three lines or more. More than nine in ten avoided a three-line loss. Those are the headline macular degeneration injections results that most current expectations are built on.

Read them carefully. The average gain is real but modest. The large majority of eyes did not have a dramatic improvement; they stopped getting worse, which in a disease that can strip central vision within months is the main event. A minority saw a substantial recovery, typically eyes where fluid had recently arrived and the underlying cells were still alive. A small minority lost vision despite treatment.

There is a second kind of result your team watches even more closely: the anatomy. On OCT, a ‘dry’ macula, one without fluid pockets, is the immediate goal of each injection. Fluid often clears within weeks of treatment, well before the letter chart catches up, and a dry scan is usually what earns you a longer gap until the next visit.

What the chart cannot show is quality of vision. Two people with the same letter score may differ in distortion, contrast and reading speed. Tell your team what has changed at home, not only what you can read on the wall.

Slowing loss, not undoing it: why scar tissue sets the limit

Picture water leaking onto a wooden floor. Mop it within the hour and the boards recover. Leave it a season and they warp, and no amount of mopping straightens them. The macula behaves much the same way, which is why the title of this article matters.

The retina’s photoreceptors, the rod and cone cells that turn light into signal, do not regenerate. When fluid lifts them away from their support layer, they falter but can survive for a time. Remove the fluid and many recover, which is where the vision gains in trials come from. Let the leak persist and two things follow. The cells die, and the body walls off the abnormal vessels with fibrous tissue, forming what specialists call a disciform scar. A scar does not leak, but it does not see either.

This is the mechanism behind two pieces of guidance that appear across the National Eye Institute, NHS and Mayo Clinic material. First, new distortion or a new central blank spot should be assessed quickly, because the interval between leak and scar is measured in weeks. Second, injections continue after vision stabilizes because the vessels are being suppressed, not removed; stop the signal-blocking and they can reactivate.

It also explains the variation between neighbors in the waiting room. Someone whose leak was caught at the first bent line has healthy cells to protect and a fair chance of some improvement. Someone who arrived after months of blurring may have a scar at the center already; injections can still protect the surrounding retina and the other eye’s future, but the central damage stands.

None of this is a reason for despair, and it is not a reason to skip treatment. It is a reason to act early and to expect the right thing.

Who is usually offered injections, and who is usually asked to wait

Anti-VEGF injections are offered for active wet AMD: abnormal vessels with fluid or bleeding under or within the macula, confirmed on OCT and often on a dye-based photograph called fluorescein angiography, in which a dye injected into an arm vein highlights leaking vessels in the back of the eye. When those findings are present in an eye with anything left to protect, treatment is usually recommended promptly.

Several groups are commonly asked to wait or are guided elsewhere:

• People with early or intermediate dry AMD. There is no leak to block, so anti-VEGF has no target. Monitoring, risk-factor work and, for some, the AREDS2 supplement formula are the usual approach.
• People with geographic atrophy, the advanced dry form in which patches of retinal cells have died off. In some countries, injections that block part of the immune system’s complement pathway have been approved for this. Trials show they slow the growth of atrophy patches on imaging; whether that translates into preserved everyday vision is still being studied, and your team will explain what the evidence does and does not show.
• Eyes with a long-established central scar and no fluid. Injections have nothing to dry, and a period of observation may be advised, with a low threshold to treat if fluid returns.
• People with an active eye infection or recent eye surgery, where the injection is usually delayed until the eye has settled.

The other eye deserves a word. Once one eye has developed wet AMD, the fellow eye is at higher risk, and it is usually scanned at every visit even when it feels fine. Some of the best outcomes in clinic come from a second eye caught at its very first leak.

Who is ‘usually’ offered treatment is a description of guideline practice, not a rule for your case. Your retina team weighs the scans, your general health and your priorities.

How often are eye injections for macular degeneration, and for how long?

The honest answer is ‘longer than most people hope, and less often than they fear.’ The NHS describes anti-VEGF treatment as a course of injections given typically every one to three months for as long as they continue to help, and Mayo Clinic notes that regular injections are usually needed to keep the vessels quiet.

Most services start with a period of monthly treatment to get the leak under control, then move to one of two patterns. In a monitoring-based approach, you attend regular scans and are injected only when fluid reappears. In a treat-and-extend approach, you receive an injection at every visit and the gap between visits is lengthened, a couple of weeks at a time, while the scan stays dry, and shortened again if fluid returns. Both aim for the same thing: the fewest injections that hold the macula dry.

Why not simply stop once the scan is dry? Because the abnormal vessels are suppressed, not gone. Long-term follow-up of trial participants has shown that when treatment becomes irregular, fluid returns in a large share of eyes, and each return risks a little more permanent damage. Some eyes do become inactive after years of treatment and can be watched without injections; that judgment belongs to your team and rests on repeated dry scans over a long period.

Practically, plan for this to be part of life for years rather than months. People who do well tend to treat the clinic like a standing appointment, bring a companion for the drive home, and tell the team early about anything that might disrupt attendance, such as surgery elsewhere or a long trip, so the schedule can be adjusted rather than broken.

The interval that is right for your eye is set by its behavior on the scan, not by a calendar in a leaflet.

Dry vs wet macular degeneration: what treatment can and cannot do

Much confusion in waiting rooms comes from mixing up the forms of the disease. The same name covers three quite different situations, each with its own realistic goal.

Situation	What is happening	Usual approach	Realistic goal
Early or intermediate dry AMD	Drusen deposits and gradual thinning of the supporting layer	Monitoring, smoking cessation, AREDS2 formula for eligible people	Lower the chance of progression; vision often stable for years
Wet AMD (active)	New vessels leaking fluid and blood under the macula	Anti-VEGF injections into the eye, scans to guide timing	Dry the macula, hold vision, modest gain in a minority
Wet AMD with established scar	Vessels walled off by fibrous tissue at the center	Observation or continued injections if fluid persists	Protect surrounding retina; central loss is permanent
Geographic atrophy (advanced dry)	Patches of retinal cells have died, slowly enlarging	Monitoring; complement-pathway injections in some regions	Slow growth of patches on scans; effect on daily vision still under study

Two threads run through the table. The first is that anti-VEGF injections are specifically a wet AMD treatment; asking for them in dry disease is like asking a plumber to fix a crack in a wall with no leak behind it. The second is that no row promises to give back what is gone. Every approach on the list is preservation, and the differences are in how much there is to preserve and how quickly change would otherwise come.

A person can sit in more than one row over time, and the eyes can differ. Dry AMD can convert to wet, which is the reason for the routine scans of a ‘good’ eye, and a treated wet eye can develop atrophy beneath a dried macula years later. Your team’s language on the day, ‘active’, ‘inactive’, ‘dry’, ‘atrophy’, is describing where each eye sits in this table.

What the days and weeks after an injection usually look like

The first evening is usually the least pleasant part, and mainly because of the antiseptic. The eye feels gritty and dry, as if a grain of sand is trapped under the lid. Lubricating drops, if your team has suggested them, help more than anything else. Bright light is uncomfortable, and reading is hard because the pupil is often dilated from the scan.

A bright red patch on the white of the eye is common the next morning. This is a subconjunctival hemorrhage, a small bleed under the clear surface layer where the needle passed. It looks alarming, is painless and fades over one to two weeks like a bruise. A few dark floaters, sometimes an air bubble that looks like a black dot drifting at the bottom of vision, generally clear within a day or two.

By day two or three the eye should feel close to normal. Discomfort that increases rather than settles, or vision that gets worse over the first days, is not part of the expected pattern and should be reported the same day; the red-flag section below sets out why.

Vision changes from the medicine itself arrive on a slower clock. Fluid on OCT often begins clearing within a couple of weeks, and it is the scan at your next visit, rather than anything you notice at home, that shows whether the injection did its job. Some people notice lines straightening or print sharpening within a few weeks; many notice little change, which usually means the vision is being held rather than lifted.

Day-to-day advice from the NHS and Mayo Clinic is modest: avoid rubbing the eye, keep dirty water out of it for a few days, and check with your team before swimming or using eye makeup. Ordinary activities, including gentle exercise and screen use, are not usually restricted, but confirm any specific instructions with the service that treated you.

Eye injection side effects for macular degeneration: what is common and what is rare

A needle into the eye sounds dangerous, and it is fair to ask about risks in plain terms. The sources agree on a short list of common nuisances and a shorter list of rare but serious events.

Common and usually harmless, according to the NHS and Mayo Clinic:

• Soreness, grittiness and watering for a day, largely from the antiseptic.
• A red blotch on the white of the eye that fades over one to two weeks.
• New floaters or a small dark bubble for a day or two.
• A short-lived rise in eye pressure immediately after the injection, which is why some services check it before you leave.

Rare but serious, and the reason for the emergency numbers on your leaflet:

• Endophthalmitis, an infection inside the eye. It is uncommon after intravitreal injection, in large part because of strict antisepsis, but it can damage sight quickly and needs same-day treatment. Increasing pain, worsening redness and dropping vision in the days after an injection are its signature.
• Retinal detachment or tear, when the retina lifts from the wall of the eye; flashes, a sudden shower of floaters or a curtain across vision are the warning signs.
• Inflammation inside the eye without infection, cataract progression, and damage from the needle itself.

Because a small amount of medicine reaches the bloodstream, researchers have looked for effects on the heart and circulation. Large trials, including CATT, did not settle the question conclusively, and the risk if present appears small; your team will take your cardiovascular history into account and may discuss this in more detail if you have had a recent stroke or heart attack.

Numbers for each of these vary by study and setting, so the descriptive terms above are deliberate. If you want figures, ask your service what it has observed; a good team will tell you.

Why macular degeneration injections results can fade over years, and what if they stop working

The first year of treatment gets most of the attention because that is where trials measure. Ask a retina specialist about year five and the conversation becomes more sober. Long-term follow-up of participants from the early anti-VEGF trials, carried out roughly seven years after they enrolled, found that average vision had drifted back below the starting point, and a substantial minority had lost three or more lines. Gains in the first two years were real; keeping them was harder.

Three mechanisms explain most of that drift.

The first is under-treatment. Outside trials, people miss visits, clinics run short of slots, and intervals stretch further than the eye can tolerate. Each recurrence of fluid can leave a little more damage. The second is atrophy. Even in a macula kept dry, the supporting layer can wear away over years, and cells die without any leak at all. The third is scarring at the site of the original vessels, which slowly matures even while treatment continues.

When someone says the injections have ‘stopped working’, it usually means one of these, not that the medicine has lost its effect on VEGF. The team’s job is to work out which. If fluid persists despite regular treatment, options a specialist may consider include shortening the interval, switching to a different anti-VEGF agent within the same class, adding imaging to look for a different type of lesion, or discussing whether continued treatment still has something to protect. If the scan is dry and vision is falling, atrophy or scar is the more likely explanation, and further injections will not address it.

None of these options carries a guaranteed result, and this is an area where an honest ‘we will try this and reassess’ from your team is more valuable than false reassurance. What you can control is attendance and prompt reporting of change; those two habits are the strongest levers a patient has over long-term macular degeneration injections results.

Can macular degeneration injections restore vision? What people often get wrong

Some misunderstandings surface at nearly every first visit. Correcting them early saves disappointment later.

‘It is a one-time fix.’ It is not. The injections suppress abnormal vessels; they do not remove them. Treatment continues, at intervals set by the scan, for as long as the eye shows a reason for it.

‘Once my vision is stable I can stop.’ Stability is what continued treatment looks like from the inside. Long-term studies show that irregular treatment is a common reason for late decline.

‘The injections will bring back what I have lost.’ Sometimes vision improves, usually where fluid was recent and the cells beneath were alive. Vision lost to scar or atrophy does not return, and no injection currently available claims to regrow photoreceptors.

‘Macular degeneration means going blind.’ The National Eye Institute is clear that AMD does not cause complete blindness; it affects central vision and spares the periphery. People with advanced disease keep the sight they use to navigate a room, even when reading becomes difficult.

‘Supplements can replace the injections.’ The AREDS2 formula was studied for slowing progression in intermediate dry disease. It has no effect on an active leak and is not a substitute for anti-VEGF treatment.

‘Dry AMD can be treated with the same injections.’ There is no VEGF-driven leak in dry disease, so anti-VEGF has no target. Different approaches, with different and more limited evidence, apply to advanced dry AMD.

‘The needle goes through the pupil.’ It enters through the white of the eye, away from the cornea and lens, and you cannot see it coming.

‘If one eye did well, the other will too.’ Each eye is its own case, with its own timing, lesion type and baseline. The fellow eye is monitored precisely because it may behave differently.

Living well between injections: what the evidence supports

Injections are the medical part of the plan. A good deal of what shapes your years with AMD happens outside the clinic, and some of it has better evidence than people expect.

The Age-Related Eye Disease Studies (AREDS and AREDS2), run by the National Eye Institute, found that a specific combination of vitamins and minerals lowered the risk of progressing to late AMD by about 25% over five years in people with intermediate disease or advanced disease in one eye. It did not help people with no or early AMD, and it is not a treatment for wet disease. Whether it suits you depends on your stage, your smoking history and other medicines, so ask your team before starting.

Smoking is the strongest modifiable risk factor for AMD across major sources, and stopping matters at any age. Diets rich in dark leafy greens and oily fish are associated with lower risk in observational studies; that is a pattern, not proof, but it is a pattern that aligns with heart health, so there is little to lose.

Self-monitoring is where you can make a real difference to results. An Amsler grid is a simple square of graph paper with a central dot; you look at the dot with one eye at a time and note any lines that bend, blur or vanish. Checked daily in good light, it can flag a new leak, especially in the fellow eye, weeks before a scheduled scan. Any new change earns a phone call, not a wait for the next appointment.

Low-vision support is under-used. Task lighting, larger fonts, high-contrast settings on phones, magnifiers and rehabilitation services do not change the retina, but they change what a person can do with the retina they have. Ask about a referral early rather than after reading has become a struggle.

Questions to ask your care team

Clinic visits are brief and often follow a scan you have not seen. Arriving with a few questions turns a procedure into a conversation. Consider bringing a companion to take notes; dilated eyes make writing hard.

• What does today’s scan show compared with the last one, and is there still fluid?
• Is this eye active or inactive right now, and what does that mean for the next interval?
• What is the realistic goal for this eye: holding vision, gaining some, or protecting what is around a scar?
• Which pattern are you following, monitoring-based or treat-and-extend, and what would make you change the gap?
• How is my other eye, and what should I watch for at home that would bring me in sooner?
• Which changes after an injection are expected, and which should prompt a same-day call?
• Does my heart or circulation history affect the choice of medicine or the schedule?
• Am I a candidate for the AREDS2 formula, and does it interact with anything I take?
• If treatment stops holding the fluid, what options would you consider, and how would we know it is time?
• Is there a low-vision service you can refer me to, and when would you suggest it?
• What is the plan if I have to miss a visit for surgery, illness or travel?

Notice what is not on the list. Questions about which clinic or which specialist is ‘best’ rarely help, because the levers that matter, early presentation, regular attendance and prompt reporting, are largely in your hands wherever you are treated. Questions about how many injections you will need in total are ones no honest team can answer in advance; the disease sets the pace.

Write down the answers, including the interval agreed for next time. People who know their own plan miss fewer visits, and missed visits are where results are most often lost.

When to call your doctor: red-flag signs after an eye injection

Most post-injection symptoms fade within a day or two. A short list should not be waited out, because the serious complications of intravitreal injection are treatable when caught quickly and sight-threatening when they are not. Your service should have given you a number to call at any hour; use it.

Call the same day, or attend urgent eye care, if in the days after an injection you notice:

• Pain that is increasing rather than easing, particularly deep, aching pain.
• Redness that is spreading or worsening after the first day, or a yellow discharge.
• Vision that is getting worse, cloudier or dimmer over hours or days instead of clearing.
• New sensitivity to light that was not present on the day of the injection.

Together these are the pattern of endophthalmitis, infection inside the eye, and time matters.

Call urgently at any point, whether or not you have had a recent injection, if you notice:

• A sudden shower of new floaters, flashes of light, or a shadow or curtain moving across part of your vision, which can signal a retinal tear or detachment.
• A new bend, wobble or gap in straight lines, or a new blank patch in the center, in either eye. In a treated eye this may mean fluid has returned; in the fellow eye it may be the first sign of a new leak. Both are reasons to be seen within days, not at the next routine visit.

Sudden loss of vision in one eye, with or without pain, warrants emergency assessment regardless of the cause you suspect.

If you are unsure whether a symptom counts, call anyway. Retina teams would far rather hear about ten harmless red patches than miss one infection. Take your appointment card or medication list with you, note the date and time of your last injection, and do not drive yourself if your vision is affected.

Frequently asked questions

How often are eye injections for macular degeneration?

Typically monthly at first, then every one to three months depending on how the macula looks on scans, according to the NHS and Mayo Clinic. Many services lengthen the gap while the scan stays dry and shorten it if fluid returns. The interval is set by the eye’s behavior rather than a fixed calendar, and only your retina team can say what fits your case.

Can macular degeneration injections restore vision?

Sometimes partly, but not reliably. In the CATT trial roughly one in four to one in three eyes gained three or more lines after a year of monthly treatment, usually where fluid was recent. Vision lost to scar or atrophy does not come back, because retinal photoreceptors do not regenerate. The realistic aim is to hold what remains and to catch new leaks early.

What are the most common eye injection side effects for macular degeneration?

A gritty, sore eye for a day, a red patch on the white of the eye that fades over one to two weeks, and a few floaters. These are expected and settle on their own. Rare serious problems include infection inside the eye and retinal detachment; increasing pain, worsening redness or falling vision in the days after an injection should be reported the same day.

Do anti-VEGF injections for wet AMD hurt?

Most people describe pressure or a brief sting rather than pain, because numbing drops or gel are used first. The stinging and grittiness afterward come mainly from the iodine antiseptic, not the needle, and lubricating drops usually help. If pain increases over the following days instead of easing, that is not typical and you should contact your eye service promptly.

How long will I need injections for wet macular degeneration?

Usually for years, at intervals that change over time. The abnormal vessels are suppressed rather than removed, so stopping tends to let fluid return. Some eyes become inactive after long treatment and can be monitored without injections, but that judgment rests on repeated dry scans and belongs to your retina team. Plan for treatment as an ongoing part of life rather than a short course.

Can I drive after an eye injection?

Not on the day. The treated eye will be blurry, the pupil is often dilated from the scan, and bright light is uncomfortable for several hours. Arrange a ride or transport to and from each visit. Driving on other days depends on your overall vision meeting the legal standard where you live, which your eye team can discuss with you.

What happens if I miss an injection?

One delayed visit is rarely a disaster, but repeated gaps are the most common reason long-term results slip. Fluid can return within weeks, and each recurrence risks a little more permanent damage. Call the service as soon as you know you will miss an appointment so it can be rebooked, and report any new distortion or blank spot straight away rather than waiting.

Do injections work for dry macular degeneration?

Anti-VEGF injections do not, because dry AMD has no leaking vessels for them to act on. For advanced dry disease called geographic atrophy, injections targeting the complement pathway are approved in some countries and have been shown to slow the growth of atrophy patches on scans; whether that preserves everyday vision is still being studied. Your team can explain the current evidence.

Are there alternatives to injections for wet AMD?

Anti-VEGF injections are the standard first-line treatment in current guidance. Older approaches, such as laser to seal vessels or photodynamic therapy using a light-activated drug, are now used only in specific situations because they can damage surrounding retina or are less effective for most lesion types. Your retina specialist can explain whether any alternative applies to your eye.

Will my other eye need injections too?

Not necessarily, but it is at higher risk once one eye has developed wet AMD, so it is usually scanned at every visit. Checking an Amsler grid daily with each eye separately can flag a new leak early, when treatment has the most to protect. Report any new bent lines or central blank spot in the fellow eye within days.

References

• National Eye Institute (NIH): Age-Related Macular Degeneration
• NHS: Age-related macular degeneration (AMD)
• Cleveland Clinic: Macular Degeneration
• National Eye Institute (NIH): Age-Related Eye Disease Studies (AREDS/AREDS2)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.